Development of cladribine treatment in multiple sclerosis

Multiple Sclerosis

Volumn 1, Issue 6, 1996, Pages 343-347

  Sipe, J C ^a   Romine, J S ^a   Koziol, J A ^a   McMillan, R ^a   Zyroff, J ^a   Beutler, E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Cladribine; Immunosuppression; Multiple sclerosis

Indexed keywords

CLADRIBINE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; HUMAN; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL;

CLADRIBINE; CROSS-OVER STUDIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS;

EID: 0030177978     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859600100612     Document Type: Article

References (22)

1. Beutler E. (1992) Cladribine (2-chlorodeoxyadenosine). Lancet 340: 952-956.
2. Beutler E. (1994) New chemotherapeutic agent: 2-chlorodeoxyadenosine. Semin Hematol 31: 40-45.
3. Beutler E et al. (1994) Marrow suppression produced by repeated doses of cladribine. Acta Haematol 91: 10-15.
4. Beutler E et al. (1991) 2-Chlorodeoxyadenosine (2-CdA): A potent chemotherapeutic and immunosuppressive nucleotide. Leuk Lymphoma 5: 1-8.
5. Beutler E et al. (1996) The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 93: 1716-1720.
6. Carson DA et al. (1979) Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci USA 76: 2430-2433.
7. Carson DA, Kaye J, Seegmiller JE. (1977) Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s). Proc Natl Acad Sci USA 74: 5677-5681.
8. Carson DA, Seto S, Wasson DB, Carrera CJ. (1986) DNA strand breaks, NAD metabolism, and programmed cell death. Exp Cell Res 164: 273-281.
9. Carson DA, Wasson DB, Beutler E. (1984) Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci USA 81: 2232-2236.
10. Carson DA et al. (1980) Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 77: 6865-6869.
11. Carson DA et al. (1982) A potent new anti-lymphocyte agent: 2-chlorodeoxyadenosine. Blood 60(Suppl 1): 161. (Abstract)
12. Carson DA, Wasson DB, Taetle R, Yu A. (1983) Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62: 737-743.
13. Giblett ER et al. (1972) Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2: 1067-1069.
14. Grieb P et al. (1994) Cladribine treatment of multiple sclerosis. Lancet 344: 538.
15. Liliemark J et al. (1992) On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: Alternative routes of administration. J Clin Oncol 10: 1514-1518.
16. Piro LD, Carrera CJ, Carson DA, Beutler E. (1990) Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322: 1117-1121.
17. Piro LD et al. (1992) Prolonged complete remissions following 2-chlorodeoxyadenosine (2-CdA) in hairy cell leukemia (HCL). Proc Am Soc Clin Oncol 11: 259. (Abstract)
18. Saven A et al. (1991) 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma 5(Suppl): 133-138.
19. Saven A et al. (1992) 2-Chlorodeoxyadenosine: An active agent in the treatment of cutaneous T-cell lymphoma. Blood 80: 587-592.
20. Saven A, Figueroa ML, Piro LD, Beutler E. (1992) Complete hematological remissions in chronic myelogenous leukemia (CML) following 2-chlorodeoxyadenosine (2-CdA). Proc Am Soc Clin Oncol 11: 261. (Abstract)
21. Saven A et al. (1993) 2-Chlorodeoxyadenosine dose escalation in non-hematologic malignancies. J Clin Oncol 11: 671-678.
22. Sipe JC et al. (1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344(No. 8914): 9-13.